top of page
Blog Posts
Search


The $10 billion unicorn in INmune Bio: reported biomarkers allow stabilization or improvement of cognition
Introduction Novel biomarkers are changing the field drastically. They allow a view into the brain, whether through PET, MRI or...
Carl Kestens
2 days ago11 min read
287 views
0 comments


The $10 billion unicorn in INmune Bio: KOL interview with Prof. Kate Lykke Lambertsen
One motor neuron, two microglia, and two astrocytes. (c) NeuroWoodworks.com , reproduced with authorization. https://x.com/NeuroWoodworks...
Carl Kestens
May 1210 min read
653 views
0 comments


On The Possible, part 2: Review of Martin Shkreli’s Live Stream On INmune Bio
Introduction INmune Bio (INMB) is developing a novel therapy targeting neurodegenerative diseases, particularly Alzheimer’s disease (AD)....
Carl Kestens
May 729 min read
245 views
0 comments


The $10 billion unicorn in INmune Bio: On The Possible, part 1
Introduction INmune Bio (INMB) is developing a novel therapy targeting neurodegenerative diseases, particularly Alzheimer’s disease (AD)....
Carl Kestens
May 622 min read
539 views
1 comment


The $10 billion unicorn in INmune Bio: viruses as drivers of inflammatory neurodegeneration
Summary " Scientists have found new solution for the treatment of Alzheimer’s disease. " The media coverage of preclinical discoveries or...
Carl Kestens
Apr 2511 min read
225 views
0 comments


Correction of mistakes mentioned in Paurana Capital short report
Stephen Bogle, an incoming Masters of Financial Economics candidate at the University of Toronto publishing under ‘Paurana Capital’ [1] ,...
Carl Kestens
Apr 232 min read
333 views
0 comments


The $10 billion unicorn in INmune Bio: cognition matters - on EMACC, CDR-SB, and why others may have failed
Summary Alzheimer’s is a disease of slowly fading cognition. If you would ask me how much my grandmother’s Alzheimer’s progressed over...
Carl Kestens
Apr 1115 min read
433 views
4 comments


The $10 billion unicorn in INmune Bio: on BioVie teachings and trustworthiness
Summary BioVie always argued that it saw a correlation between effects on cognition and reduction of TNF levels. That TNF reduction...
Carl Kestens
Mar 1410 min read
388 views
2 comments


The $10 billion unicorn in INmune Bio: Leqembi and Kisunla’s MoA is microglia-related, and amyloid beta is a cytokine
Introduction Amyloid beta has been the primary hallmark of Alzheimer’s disease for years. On the one hand, numerous trials focusing on...
Carl Kestens
Mar 615 min read
398 views
13 comments


The $10 billion unicorn in INmune Bio: where fraud and arrogance aren’t, solutions to AD are (C. Piller book coverage)
Introduction Science journalist Charles Piller wrote a book, called ‘Doctored: fraud, arrogance, and tragedy in the quest to cure...
Carl Kestens
Feb 2810 min read
385 views
1 comment


The $10 billion unicorn in INmune Bio: XPro’s biomarkers outperform Leqembi's and Kisunla's
Introduction For years, the scientific focus may have been too focused on targeting amyloid, while inflammation and modulation of glial...
Carl Kestens
Feb 215 min read
354 views
0 comments


The $10 billion unicorn in INmune Bio: inflammation drives cognitive decline
Summary INmune Bio is making significant strides across multiple programs, positioning itself as a major player in biotech. CORDstrom...
Carl Kestens
Feb 1311 min read
248 views
0 comments


The $10 billion unicorn in INmune Bio: On Cassava Sciences and the Importance of a Bear Thesis for Proper Due Diligence
Summary Coverage of the Alzheimer’s space would be incomplete without a blog post on Cassava Sciences. Now was the right time. Cassava...
Carl Kestens
Feb 711 min read
535 views
1 comment


The $10 billion unicorn in INmune Bio: Alzheimer’s, How Not To Study A Disease
On JLO, RFK, the NIH, TNF, Karl Herrup and innovation - a longer post. Â Summary The amyloid hypothesis did not yield the desired...
Carl Kestens
Jan 3113 min read
826 views
0 comments


The $10 billion dollar unicorn in INmune Bio: is the FDA openly suggesting accelerated approval based on NfL?
Summary I had a call with some investors earlier this week. During the call, the theme of accelerated approval came up. I had done a blog...
Carl Kestens
Jan 249 min read
534 views
0 comments


The $10 billion unicorn in INmune Bio: how only INMB uses the recipe behind big pharma’s recent successes with anti-amyloid antibodies
Historical failure rate of therapies targeting amyloid Alzheimer’s is characterized by aggregation of anti-amyloid antibodies and...
Carl Kestens
Jan 177 min read
699 views
0 comments


The $10 billion dollar unicorn in INmune Bio: could remyelination explain the fast functional/cognitive recovery seen in patients?
Introduction I am picking up my previous work to assess the Alzheimer’s space today, with a particular focus on INmune Bio, as the...
Carl Kestens
Jan 106 min read
1,053 views
0 comments


The $10 billion dollar unicorn in INmune Bio: on fast-progressors in AD, APOE4, TREM2 and EMACC
Summary APOE4, involved in different mechanisms in the brain including lipid homeostasis, is the strongest risk factor for Alzheimer’s...
Carl Kestens
Oct 21, 202212 min read
747 views
0 comments


The $10 Billion unicorn in INmune Bio: the potential of XPro in Parkinson’s
Summary The evolution of the treatment failures for Parkinson’s disease has striking similarities with Alzheimer’s. Just like in...
Carl Kestens
Sep 23, 202212 min read
630 views
0 comments


The FDA’s two leaps at once: on fast approval pathways and neurofilament light
Summary Neurofilament Light (NfL) is potentially the most important biomarker in neurodegenerative diseases. The FDA’s AdCom validated...
Carl Kestens
Sep 2, 20228 min read
638 views
0 comments
bottom of page